Anti-programmed death-1 receptor (anti-PD-1) and anti-programmed death-ligand 1 (PD-L1) inhibitors are the most rigorously evaluated immune checkpoint inhibitors and have been found to be efficacious in various tumour types, including in subsets of gastric cancers [55,56,57,58]. The gene discussed is CD274; the disease is gastric cancer.